Ji Xing Pharmaceuticals
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ji Xing Pharmaceuticals
Lessons Still To Learn: Cytokinetics’ Omecamtiv Is Over In The US, But FDA Debriefs Could Inform European Strategy
Cytokinetics will not conduct the new trial in heart failure with reduced ejection fraction (HFrEF) required by the FDA’s complete response letter for omecamtiv mecarbil.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.
Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.